3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Interventions
Nivolumab
5
aldesleukin
3
Ipilimumab
3
Blood Specimen Collection
3
relatlimab
2
Vemurafenib
2
Immune Checkpoint Inhibitors
2
trametinib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
technetium Tc 99m nanocolloid
1
sargramostim
1
pembrolizumab
1
pasireotide
1
encorafenib
1
dabrafenib
1
binimetinib
1
Vindesine
1
Standard of Care
1
Specimen Handling
1
Sevoflurane
1
Propofol
1
Pharmaceutical Preparations
1
Patient-Specific Modeling
1
Isoflurane
1
Interleukins
1
Interleukin-2
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fibrin Tissue Adhesive
1
Etanercept
1
Desflurane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Melanoma
×
Interleukins
×
Clear all
NCT01856023
2023-12-05
PROCLIVITY02
Clinigen, Inc.
Phase 4
Terminated
29 enrolled
9 charts